Can ADHD One Day Be Diagnosed Like a Broken Bone? New Paths from Dopamine to DNA
Scientists are closing in on a biological test for ADHD that could replace symptom checklists. In a bustling pediatric hallway, a teenager known for “being in his own world” shuffles to the exam room, his eyes flicking to the clock. For clinicians, the scene is familiar: a patient whose impulsivity, inattention and inner turbulence have been diagnosed by questionnaires, not by a lab test. A new OpenAlex review, The identification of new directions for the research of ADHD (2023), argues that this reliance on subjective reports is about to change.
The authors map a crossroads: on one side sits a century‑old diagnostic model built on behavior; on the other, emerging tools—genetic screening, neurochemical mapping, advanced brain imaging—that could let doctors see ADHD the way they see a broken bone on an X‑ray. The review offers no new data, but it weaves together a clear picture of where the science is headed and why those directions matter for the millions who live with the disorder.
The Diagnostic Dilemma: Why a Test Matters
ADHD has long been labeled a “behavioral” disorder, diagnosed through questionnaires such as the DSM‑5 criteria. The abstract notes a striking epidemiological shift: “adult cases of ADHD have been on the rise.” Recent surveys suggest that up to half of those diagnosed in childhood continue to meet criteria as adults.
Subjective assessment brings two major risks. First, it leaves room for over‑ or under‑diagnosis, especially where cultural norms around activity and attention differ. Second, it complicates treatment decisions. Stimulant medications—methylphenidate and amphetamines—are the most effective pharmacologic options, yet they are “heavily restricted” because of addiction potential and cardiovascular concerns. Without an objective biomarker, clinicians must weigh symptom relief against the specter of misuse, often with limited guidance.
Comorbidities—anxiety, autism spectrum disorder (ASD), depression—further entangle the picture. A recent narrative review of ASD in Advanced Neurology highlighted overlapping neurodevelopmental pathways, suggesting shared genetic and neurochemical mechanisms could blur diagnostic boundaries. Likewise, a systematic review on impulsivity and self‑harm in adolescents (Asian Journal of Human Services) showed that impulsivity, a core ADHD trait, predicts risky behaviors across disorders. These intersections reinforce the authors’ call for a “reliable identification” of ADHD through biomarkers and brain scans.
Dopamine’s Double‑Edged Role
The dopamine system has been the centerpiece of ADHD research for decades. The OpenAlex paper restates the prevailing model: individuals with ADHD exhibit “lower levels of dopamine,” and the most common pharmacotherapies work by boosting dopamine availability. The authors push beyond the simple “dopamine deficiency” narrative.
They propose a “signaling cascade that is continuously active.” In this view, insufficient dopamine fails to terminate a cascade of intracellular signals, leading to prolonged abnormal expression of downstream genes and receptors. This could explain why stimulant medications, which raise synaptic dopamine, often have rapid therapeutic effects—by providing the missing “off‑switch” for the cascade.
The review also emphasizes the interplay between dopamine, norepinephrine, and serotonin. Each neurotransmitter modulates the others, forming a feedback loop that regulates attention, arousal and mood. Disruption at any node can ripple through the network, potentially accounting for the wide symptom spectrum and frequent comorbidities. While no new experimental data are presented, the synthesis suggests future research should target the cascade’s regulatory checkpoints rather than dopamine alone.
Genetics and Brain Architecture: Seeds of a Disorder
If neurotransmitters are the messengers, genetics may be the blueprint. The authors note that “genetic testing” can illuminate “areas of interest” for ADHD research. Genome‑wide association studies (GWAS) have identified dozens of loci linked to attention regulation, many involving genes that shape dopamine transporters, receptor density and synaptic plasticity. The OpenAlex article highlights the growing feasibility of integrating polygenic risk scores into clinical practice.
Structural brain differences have long been observed in ADHD cohorts. Magnetic resonance imaging (MRI) studies consistently report reduced volume in the prefrontal cortex, basal ganglia and cerebellum—regions integral to executive function and motor control. The authors suggest that such morphological changes may arise from “genetic disorders or brain injury,” making ADHD both a symptom and a potential cause of broader neurodevelopmental disruption.
Crucially, the paper argues that genetics and brain structure should be examined together. Linking specific genetic profiles to neuroimaging phenotypes could clarify why some individuals respond dramatically to stimulants while others experience minimal benefit or adverse effects.
Imaging and Biomarkers: Toward an Objective Test
Perhaps the most tantalizing prospect raised by the review is the use of biomarkers and brain scans for diagnosis. Functional MRI (fMRI) can map real‑time activity in dopamine pathways, while positron emission tomography (PET) can directly measure dopamine transporter density. Early pilot studies have demonstrated distinct activation patterns in ADHD participants during tasks requiring sustained attention.
The authors caution that “currently, ADHD cannot be detected by a test.” They advocate for a multimodal diagnostic algorithm that integrates genetic risk scores, neurotransmitter imaging and behavioral assessments. In theory, such a framework could differentiate ADHD from other neurodevelopmental conditions that share overlapping symptoms—like ASD or anxiety disorders—by pinpointing unique neurochemical signatures.
Emerging peripheral biomarkers, such as altered catecholamine levels in blood or urine and epigenetic marks reflecting environmental influences on gene expression, are also discussed. None have achieved clinical validation, but the authors view them as promising pieces of a larger puzzle.
From Theory to Practice: Challenges and Opportunities
Translating these directions into everyday tools will not be straightforward. High‑cost imaging techniques like PET are not widely available, and the ethical implications of genetic screening in children remain contentious. Moreover, the heterogeneity of ADHD—manifesting differently across age, gender and cultural contexts—means that a single biomarker is unlikely to capture the full spectrum.
Nevertheless, the authors remain optimistic. Incremental steps—standardizing fMRI protocols for attention tasks or developing affordable blood‑based assays—could gradually reduce reliance on subjective checklists. They also stress interdisciplinary collaboration, bringing together neuroscientists, geneticists, clinicians and even media scholars (as illustrated by a related study on emotional involvement in short audiovisual stories) to communicate findings in ways that resonate with patients and families.
The paper’s vision is a future where a teenager like the one in the clinic hallway could receive a concise, evidence‑based diagnosis—perhaps a blood draw and a brief scan—followed by a personalized treatment plan that balances efficacy with safety. Until then, the field must navigate the “complex disorder” of ADHD with both scientific rigor and compassionate care.
What it does not prove
- The OpenAlex article is a review and perspective, not a primary research study; it does not present new experimental data.
- No single biomarker or imaging technique is currently validated for diagnosing ADHD; the proposed directions remain hypotheses awaiting large‑scale testing.
- The suggested “signaling cascade” model is theoretical; its exact molecular components and therapeutic targets have not been empirically confirmed.
- Genetic risk scores, while promising, do not yet predict individual treatment response or guarantee a diagnosis.
- The review does not address cost‑effectiveness, accessibility or ethical considerations of implementing genetic or imaging diagnostics in routine practice.
Frequently asked questions
1. Is there a blood test for ADHD?
No. Researchers are exploring peripheral markers such as catecholamine levels, but none have achieved the sensitivity or specificity needed for clinical use.
2. Can brain scans replace behavioral assessments?
Not at present. Functional and structural imaging can reveal patterns associated with ADHD, yet they are not definitive enough to serve as standalone diagnostic tools.
3. Do genetics determine whether someone will develop ADHD?
Genetics contribute to risk—GWAS have identified multiple risk loci—but environmental factors, brain injury and developmental influences also play significant roles.
4. Are stimulant medications the only effective treatment?
Stimulants are the most widely studied and generally the most effective pharmacologic option, but non‑stimulant medications, behavioral therapy and lifestyle interventions are also part of comprehensive care.
5. How soon might an objective ADHD test become available?
Experts estimate that reliable, clinically viable biomarkers could be a decade away, pending large‑scale validation studies and regulatory approval.
Sources
- The identification of new directions for the research of ADHD. OpenAlex (2023). https://doi.org/10.54014/3nav-mt8w
- Emotional Involvement in Audiovisual Stories for New Media. Hipertext net (2026). https://doi.org/10.31009/hipertext.net.2026.i32.03
- The Role of Impulsivity in the Onset and Chronicity of Self‑Harm Behaviors among Adolescents. Asian Journal of Human Services (2025). https://doi.org/10.14391/ajhs.e3003.2.002
- A multidimensional review of autism spectrum disorder in Türkiye and the world. Advanced Neurology (2024). https://doi.org/10.36922/an025250073
Educational Disclaimer
This article is for informational and educational purposes only. It is not
medical advice, mental health advice, diagnosis, treatment guidance, or a
recommendation to use any substance, supplement, therapy, or protocol.
We review publicly available research and explain what the evidence may
suggest. Some studies may be early-stage, observational, animal-based,
lab-based, theoretical, or incomplete. Always consult a qualified
professional before making health-related decisions.
Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.
